Sign In
Buy WXXWY
$9.88
+0.180 (+1.86%)
At Close: Jul 31, 2026
WuXi Biologics Reports Record 2025 Annual Results
07:44am, Tuesday, 24'th Mar 2026
Revenue increased 16.7% YoY to RMB 21.8 billion, and revenue from continuous operations grew over 20% YoY IFRS gross profit margin expanded to 46.0% (+500 bps YoY); adjusted gross profit margin increa
World Water Day: WuXi Biologics Advances Water Stewardship and Achieves Water Target
09:30pm, Saturday, 21'st Mar 2026
SHANGHAI, March 21, 2026 /PRNewswire/ -- On the occasion of World Water Day, WuXi Biologics reaffirms its commitment to sustainability through responsible operations and efficient, circular water‑us
SINGAPORE, March 12, 2026 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it has won six p
WuXi Biologics Included in S&P Global Sustainability Yearbook for Fourth Consecutive Year
10:21pm, Sunday, 01'st Mar 2026
SHANGHAI, March 1, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced it has been included in the S&P Glob
WuXi Biologics Awarded EcoVadis Platinum Medal for Third Consecutive Year, Ranking Among Top 1% Globally
09:30pm, Sunday, 08'th Feb 2026
SHANGHAI, Feb. 8, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), announced it has been awarded a Platinum Medal by the EcoVadis Sustainability Rating, marking the third year the company has received
SHANGHAI, Jan. 28, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), and Sinorda Biomedicine today jointly announc
Short Interest in WuXi Biologics (Cayman) Inc. (OTCMKTS:WXXWY) Drops By 70.7%
03:11am, Wednesday, 28'th Jan 2026
WuXi Biologics (Cayman) Inc. (OTCMKTS:WXXWY - Get Free Report) was the target of a large drop in short interest during the month of January. As of January 15th, there was short interest totaling 22,35
SHANGHAI, TAIPEI and SAN FRANCISCO, Jan. 26, 2026 /PRNewswire/ -- HanchorBio, Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology an
WuXi Biologics (Cayman) Inc. (OTCMKTS:WXXWY) Sees Large Growth in Short Interest
01:19am, Friday, 16'th Jan 2026
WuXi Biologics (Cayman) Inc. (OTCMKTS:WXXWY - Get Free Report) saw a significant growth in short interest in December. As of December 31st, there was short interest totaling 76,332 shares, a growth of
JPM Highlights | WuXi Biologics CEO Dr. Chris Chen: Scaled CRDMO Platform Delivering Sustainable High Growth
11:00pm, Wednesday, 14'th Jan 2026
Total of 945 integrated projects in 2025, including 74 Phase III clinical projects and 25 commercial manufacturing projects 209 new integrated projects in 2025 set a new record, with approximately 50%
WuXi Biologics (Cayman) Inc. (WXXWY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
08:05pm, Wednesday, 14'th Jan 2026
WuXi Biologics (Cayman) Inc. (WXXWY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
WuXi Biologics Obtains GMP Certification from UK MHRA for Commercial Manufacturing of an Ophthalmic Biologic
10:07pm, Monday, 12'th Jan 2026
WUXI, China, Jan. 12, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), announced that two of its manufacturing f
WuXi Biologics Launches Industry-Leading Digital Twin Platform PatroLab™ Designed to Transform Bioprocessing and Manufacturing
08:09am, Monday, 12'th Jan 2026
SHANGHAI, Jan. 12, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced the launch of PatroLabTM, a s
WuXi Biologics Achieves ISO 20400 Certification, Setting Benchmark in Sustainable Procurement
10:57pm, Sunday, 04'th Jan 2026
WUXI, China, Jan. 4, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK) announced it has achieved ISO 20400 Sustainable Procurement certification, an internationally recognized standard that integrates sus
WuXi Biologics Recognized by Hong Kong ESG Reporting Awards 2025 for Outstanding ESG Disclosure
11:30pm, Tuesday, 23'rd Dec 2025
HONG KONG , Dec. 23, 2025 /PRNewswire/ -- WuXi Biologics (2269.HK) has once again raised the bar for sustainability commitment and transparency. The company has been honored by the Hong Kong ESG Repo
